RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:300888

Diffuse large B-cell lymphoma with chronic inflammation

high confidenceDisorder

Also known as: DLBCL with chronic inflammation

Publications

26

35.6th percentile

Trials

0

Interventional, condition-specific

Researchers

194

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Diffuse large B-cell lymphoma with chronic inflammation is an Epstein-Barr virus-associated malignant lymphoproliferative disorder, developing in a context of long-standing or slow-growing, chronically inflamed lesions, such as chronic pyothorax, metallic implants in bones and joints, chronic osteomyelitis, chronic venous ulcer, or, rarely granulomatous inflammation. The tumor is usually primarily localized, with no involvement of other organs.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    26 matched papers (18 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 1023 for broader category diffuse large B-cell lymphoma

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

26

26 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

26 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

18 in the last 10 years · high confidence · 35.6th percentile (publications denominator)

Phrase hits: 26 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

194

Distinct author names in 26 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Nakamura S2 papers · 2023

    Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya 466-8550, Japan.

    Papers in Europe PMC
  2. 02
    Quintanilla-Martinez L2 papers · 2025

    Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany. Leticia.quintanilla-fend@med.uni-tuebingen.de.

    Papers in Europe PMC
  3. 03
    Aglan A1 paper · 2021

    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

    Papers in Europe PMC
  4. 04
    Altmann H1 paper · 2025

    Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

    Papers in Europe PMC
  5. 05
    Anagnostopoulos I1 paper · 2025

    Institute of Pathology, Julius-Maximilians-University Würzburg, Würzburg, Germany.

    Papers in Europe PMC
  6. 06
    André M1 paper · 2026

    Hematology Department, CHU UCL Namur, Yvoir, 5530, Belgium.

    Papers in Europe PMC
  7. 07
    Balagué O1 paper · 2025

    Department of Pathology, Hospital Clinic, Barcelona, Spain.

    Papers in Europe PMC
  8. 08
    Banaszkiewicz P1 paper · 2017

    Department of Trauma and Orthopaedics, Queen Elizabeth Hospital, Gateshead Health NHS Foundation Trust, Sheriff Hill, Gateshead NE9 6SX, UK.

    Papers in Europe PMC
  9. 09
    Barrionuevo C1 paper · 2023

    Department of Pathology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú.

    Papers in Europe PMC
  10. 10
    Baur R1 paper · 2025

    Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen and University Hospital Erlangen, Erlangen, Germany.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 1,023 trials are registered for diffuse large B-cell lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

1,023 interventional trials matched diffuse large B-cell lymphoma, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: diffuse large B-cell lymphoma

1,023

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Diffuse large B-cell lymphoma with chronic inflammation" OR "DLBCL with chronic inflammation"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Diffuse large B-cell lymphoma with chronic inflammation" OR "DLBCL with chronic inflammation"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"diffuse large B-cell lymphoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T12:45:19.779Z